Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.
about
Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivoSlipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistanceSelective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapyAbsence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected miceOncolytic virotherapy using herpes simplex virus: how far have we come?Oncolytic virus therapy for glioblastoma multiforme: concepts and candidatesVisualization of mouse neuronal ganglia infected by Herpes Simplex Virus 1 (HSV-1) using multimodal non-linear optical microscopyAntiviral drug resistance: mechanisms and clinical implicationsInhibition of herpes simplex virus reactivation by dipyridamoleInhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complexDe novo synthesis of VP16 coordinates the exit from HSV latency in vivo.A herpesvirus encoded deubiquitinase is a novel neuroinvasive determinantPreliminary study of the UL55 gene based on infectious Chinese virulent duck enteritis virus bacterial artificial chromosome cloneNelfinavir inhibits maturation and export of herpes simplex virus 1.Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicityTowards an understanding of the herpes simplex virus type 1 latency-reactivation cycleDiagnosis of genital herpes simplex virus infection in the clinical laboratoryInterferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathwayHuman thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant.The polyserine tract of herpes simplex virus ICP4 is required for normal viral gene expression and growth in murine trigeminal gangliaImmunohistochemical analysis of primary sensory neurons latently infected with herpes simplex virus type 1.Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression.Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral genome copy number latency.Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in miceOptimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.[18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis.Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread.Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.An unusual internal ribosome entry site in the herpes simplex virus thymidine kinase geneMurid herpesvirus-4 lacking thymidine kinase reveals route-dependent requirements for host colonization.Herpes latency, meningitis, radiculomyelopathy and disseminated infection.Rapid phenotypic characterization method for herpes simplex virus and Varicella-Zoster virus thymidine kinases to screen for acyclovir-resistant viral infection.Herpesvirus vectors for therapy of brain tumors.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementThe dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.Herpes simplex virus DNA synthesis is not a decisive regulatory event in the initiation of lytic viral protein expression in neurons in vivo during primary infection or reactivation from latency.Oncolytic viruses as therapeutic agents.Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteinsIdentification, localization, and regulation of expression of the UL24 protein of herpes simplex virus type 1.
P2860
Q24519029-6A32B9AA-5811-4AA2-A8FF-5638F75187B8Q24634966-2A37EAA6-4798-479B-8B2F-9C1A48DE7ECBQ24679781-60185AF2-0A49-4C75-AAAB-8B15042CCAC2Q24797196-C31B68F6-416C-4367-A135-F582DC56F28AQ26862461-8399219E-E0FF-46FE-BD6E-FAF87AF276D9Q27007519-2AC2812C-4CD8-459B-B469-53E4D64C5844Q27314873-6C9C3224-F354-4119-910E-27F23458FF07Q28282376-D3CA8391-6789-4F62-8A95-632D2D2E437EQ28364147-9FDCF586-790A-42C9-B4C2-AF4CD4262A8BQ28368363-4E792390-F3B8-4F13-A932-2A3B991A3F41Q33422983-34943569-35AE-4B43-B816-374F0BBDC3A6Q33432679-0E7A6AF4-4675-46EF-8D14-5C66425C6188Q33560444-26A9A62B-EC0F-4232-A7A4-4CC8F0B32F08Q33602791-AE145302-1524-4868-BE7C-1193084A901BQ33639601-A5E02E45-0FD3-4B16-8240-DC478789F0F9Q33654414-B1FC0355-349D-40DB-98C7-902C97CE0F8EQ33655295-32B7E4D5-193A-4C1B-A960-5B6A1B2446C1Q33767327-BF59A4C0-BD2B-4BA9-9A87-2E7C8E93E84DQ33783612-CA45A5CA-C58A-40F4-AC0A-9E787D4F3BBBQ33783767-9242AE37-41EF-4D9D-B0E6-63171E665BA7Q33794645-AA8B4FC4-B6CC-4D3D-AA85-7DEE186EEAF7Q33796629-92977F2C-2F85-4147-920E-448A643FF75FQ33796650-93F3E1F6-2038-4E9B-B79C-5ED0376993C1Q33802747-39744295-AA08-441E-B4F6-7C62B1618AA9Q33806643-F54CE1D0-3943-4B41-845C-B4116673E3C1Q33843144-4289255A-5107-4761-9AAA-6D22F67187AAQ33851697-ADA36FBE-81BC-464C-A427-B0F915A18D26Q33873085-30E8CA1C-BE28-4618-9187-91E8B4FFDA7CQ33892430-34EDD331-962A-4AC5-8218-17673D6A0BC1Q33910738-A500017E-142A-45A6-A132-02BF6BB51C76Q33935057-1458B2B1-A836-402D-AEB3-56482E5F5891Q33966906-957B86BB-F577-4EF7-8695-73DD00FAF779Q34091990-8CC760AD-4A1C-434C-A976-57CE65BD3506Q34149904-B5669ACE-12BA-41E5-A7ED-8B95D5280DD3Q34150713-E731C84B-7458-4570-AC57-977827BE6740Q34232948-498A3543-18FC-4A92-B256-E19EF2AD3C03Q34329548-4D6AB5DE-5289-49DB-83F8-209B5AA9C4E5Q34339657-DC482DE8-68CC-4ADE-932F-7A420C01E743Q34343774-ADAB45CD-D55D-46DE-8676-68F33F122133Q34349368-A10464B1-19DB-48A3-B5DE-FA83D60781CB
P2860
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Thymidine kinase-negative herp ...... ganglia but do not reactivate.
@ast
Thymidine kinase-negative herp ...... ganglia but do not reactivate.
@en
type
label
Thymidine kinase-negative herp ...... ganglia but do not reactivate.
@ast
Thymidine kinase-negative herp ...... ganglia but do not reactivate.
@en
prefLabel
Thymidine kinase-negative herp ...... ganglia but do not reactivate.
@ast
Thymidine kinase-negative herp ...... ganglia but do not reactivate.
@en
P2093
P2860
P356
P1476
Thymidine kinase-negative herp ...... ganglia but do not reactivate
@en
P2093
C L Bogard
M Kosz-Vnenchak
P A Schaffer
P2860
P304
P356
10.1073/PNAS.86.12.4736
P407
P577
1989-06-01T00:00:00Z